科兴集团董事长尹卫东：当前生物医药行业有四大变化

Core Insights - The current changes in the biopharmaceutical industry are driven by four major trends: the pandemic has accelerated the application of biotechnology, creating significant health market demand; the integration of biotechnology with AI is reshaping health needs and unlocking substantial growth opportunities; the US-China rivalry poses challenges that compel China's biotechnological globalization and market adjustments; and China is leveraging its 1.4 billion domestic market to establish a global strategy in biotechnology [1] Group 1 - The biopharmaceutical industry's true path forward is to provide "global solutions" for human health, ensuring the best services and technological products meet new health demands, achieving high-quality standards to gain trust from more countries, and maximizing production at the lowest costs to make healthcare accessible [1] - The "Lai Fu Initiative" proposed by the company includes four key points: breaking down cognitive boundaries and practicing two-way openness; focusing on technological innovation to accelerate breakthroughs; upgrading cooperation dimensions to build a collaborative system across the entire industry chain; and adhering to high-quality standards to reduce costs and achieve win-win outcomes [1] Group 2 - The company advocates for the establishment of joint research and development platforms to promote shared technological achievements, accelerate product innovation cycles, and collectively seize the global biopharmaceutical technology high ground, injecting core momentum into industry development [2]